GlassScriptPhysician profile
Meredith Prevor-Weiss
NPI 1669430666
$11,307.62
in general payments reported to CMS, 2019-2025
32 companies · $1,927 in 2025
The $1,927 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $713 · 2021: $1,225 · 2022: $1,589 · 2023: $1,914 · 2024: $3,011 · 2025: $1,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,852.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,753.66 | 2019-2025 | Rocklatan, Clareon Panoptix Pro, Rhopressa |
| Bausch & Lomb Americas INC. | $1,390.17 | 2022-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| Abbvie INC. | $997.07 | 2022-2025 | |
| Horizon Therapeutics Plc | $692.70 | 2021-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $687.83 | 2019-2025 | Cequa |
| Eyevance Pharmaceuticals LLC | $606.90 | 2019-2022 | |
| Glaukos Corporation | $558.94 | 2023-2025 | Idose, Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Allergan, INC. | $471.27 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $451.04 | 2019-2021 | |
| Amgen INC. | $438.40 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $424.52 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $340.78 | 2019-2024 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Rxsight INC | $339.98 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Aerie Pharmaceuticals, INC. | $255.96 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $253.98 | 2022-2024 | Eylea Hd, Eylea |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $223.37 | 2023-2024 | Tyrvaya |
| Biotissue Holdings INC. | $184.69 | 2022 | |
| Kala Pharmaceuticals, INC. | $156.62 | 2019 | |
| Genentech USA, INC. | $150.00 | 2023 | Vabysmo |
| Sight Sciences, INC. | $146.84 | 2024 | Omni Surgical System |
| Ivantis, INC | $133.07 | 2021 | |
| Shire North American Group INC | $95.46 | 2019 | |
| Alimera Sciences, INC. | $93.94 | 2020-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $90.86 | 2023-2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $88.76 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $73.20 | 2025 | Iyuzeh |
| Harrow Eye, LLC | $70.60 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $56.46 | 2022-2025 | Dextenza |
| Rayner Intraocular Lenses Limited | $25.35 | 2025 | Omidria |
| Mallinckrodt Hospital Products INC. | $22.61 | 2025 | Acthar |
| Merz Pharmaceuticals, LLC | $19.81 | 2023 | Xeomin |
| Dompe US, INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Prevor-Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.